Diabetes Update 2010- Pharmacist

  Price  

  Credits  1.5

This product is currently out of stock and unavailable.


Format
As we learn more about the pathophysiology of type 2 diabetes mellitus (T2DM), the level of therapeutic complexity continues to grow. Whether this involves the approval of new medications, new insights into potential drug side effects, or changes in treatment goals, it is in the community provider’s best interest to stay abreast of the latest developments in the management of T2DM. This article updates the participant on 7 key developments in the treatment of T2DM: 1) saxagliptin (OnglyzaTM), the new dipeptidyl-peptidase-4 (DPP-4) inhibitor, 2) research evaluating “tight” glucose control in patients with T2DM, 3) cardiovascular risk with rosiglitazone (Avandia®) and pioglitazone (Actos®), 4) safety warnings for insulin secretagogues (i.e., sulfonylureas, meglitinides), 5) the potential link between insulin glargine (Lantus®) and cancer, 6) promising new insulin formulations through the inhaled and buccal routes of administration, and 7) liraglutide, a once-daily glucagon-like peptide-1 (GLP-1) analog similar to exenatide (Byetta®). Accompanying each review is a synopsis of pertinent patient counseling information.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 428-0000-10-001-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.